Gynecologic Cancers

The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.

Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.

Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.

“Team science is important for being open-minded [and] thinking outside of the box.”

Patients with recurrent cervical cancer appeared to achieve a promising survival benefit following treatment with cemiplimab.

The phase 3 SIENDO trial, examining the use of frontline maintenance selinexor after combination chemotherapy in patients with advanced or recurrent endometrial cancer, met its primary end point of a statistically significant improvement in progression-free survival.

Researchers prospectively analyzed the effect of implementing systemic outpatient identification on initiating goals of care conversations for high-risk patients with gynecologic cancers.

In recognition of World Cancer Day, CancerNetwork® spotlights NCCN efforts to reduce disparities in cervical cancer.

In a regulatory update on cemiplimab for advanced cervical cancer, Regeneron Pharmaceuticals announced that the agent’s biologics license application has been withdrawn.

In an interview with CancerNetwork, Don Dizon, MD, FACP, FASCO, discusses key updates that read out in both the gynecologic oncology and breast cancer fields over the course of 2021.

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

Findings from a phase 2 study demonstrated encouraging clinical activity and a manageable safety profile when patients with advanced cervical cancer were treated with second-line balstilimab and zalifrelimab.

Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.

A secondary analysis of a clinical trial indicated that women who were human immunodeficiency virus–positive and underwent loop electrosurgical excision procedure for cervical intraepithelial neoplasia had an increased likelihood of clearing high-risk human papillomavirus than women who underwent cryotherapy.

Camrelizumab plus apatinib demonstrated efficacious anti-tumor activity and could be a worthwhile salvage therapy in high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.

Patients who were carriers of pathogenic variants of for BRCA1/2 had a better physical and mental quality of life after undergoing risk-reducing salpingectomy compared with risk-reducing salpingo-oophorectomy.

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.

Use of economic coping mechanisms were associated with scoring 26 or lower on the COST analysis, or Comprehensive Score for Financial Toxicity, in patients being treated for gynecologic cancers.

The phase 2 KEYNOTE-158 trial has demonstrated promising responses in patients with microsatellite instability–high/ mismatch repair deficient advanced endometrial carcinoma, and led to the FDA accepting a review of a new supplemental biologics license application for the drug.

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.